Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-30
2003-07-22
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S227800, C514S233500, C514S236800, C514S241000, C514S247000, C514S252130, C514S252140, C514S253090, C514S253100, C514S253130, C514S254010, C514S254020, C514S254050, C514S254110, C514S314000, C514S326000, C514S342000, C514S367000, C514S397000, C514S399000, C514S402000, C514S438000, C514S439000, C514S442000, C514S443000, C514S444000, C514S456000, C514S824000, C514S838000, C514S851000, C514S866000, C514S878000
Reexamination Certificate
active
06596745
ABSTRACT:
This application claims the priority of U.S. Application No. 60/294,438, filed May 30, 2001.
The present invention relates to methods for treating certain fibrotic diseases or other indications.
Glucose and other sugars react with proteins by a non-enzymatic, post-translational modification process called non-enzymatic glycosylation. At least a portion of the resulting sugar-derived adducts, called advanced glycosylation end products (AGEs), mature to a molecular species that is very reactive, and can readily bind to amino groups on adjacent proteins, resulting in the formation of AGE cross-links between proteins. Recently a number of classes of compounds have been identified whose members inhibit the formation of the cross-links, or in some cases break the cross-links. These compounds include, for example, the thiazolium compounds described in U.S. Pat. No. 5,853,703. As AGEs, and particularly the resulting cross-links, are linked to several degradations in body function linked with diabetes or age, these compounds have been used, with success, in animal models for such indications. These indications include loss of elasticity in blood vasculature, loss of kidney function and retinopathy.
Now, as part of studies on these compounds, it has been identified that these compounds inhibit the formation of bioactive agents, such as growth factors and inflammatory mediators, that are associated with a number of indications. These agents include vascular endothelial growth factor (VEGF) and TGF[beta]. As a result, a number of new indications have been identified for treatment with agents that inhibit the formation of, or more preferably break, AGE-mediated cross-links. It is not unreasonable to infer that the effects seen are due to the removal of AGE-related molecules that provide a stimulus for the production or release of these growth factors. Removal of such molecules is believed to proceed in part due to the elimination of AGE-related cross-links that lock the AGE-modified proteins in place. Moreover, such compounds also reduce the expression of collagen in conditions associated with excess collagen production. Regardless of the mechanism, now provided are new methods of treating a number of indications.
SUMMARY OF THE INVENTION
In one embodiment, the invention relates to a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human, comprising administering an effective amount of a compound of the formula I:
wherein: W and Y are independently N or, respectively, CR
W
or CR
Y
. Z is O, S or NR
Z
. Q is —CH
2
— or —(CO)—CH
2
—, where the methylene is bonded to a ring nitrogen. R
W
and R
Y
are independently hydrogen, alkyl, —C≡CR
E
, —CH
2
—C≡CR
P
, alkenyl, aryl, arylalkyl, aryloxy, arylthio, amino, alkylamino, arylamino, dialkylamino, diarylamino, CH
3
C(O)NH—, fluoroalkyl, perfluoroaryl, hydroxyalkyl, C(O)NH
2
, and S(O)
2
NH
2
or, together with their ring carbon atoms form a fused 6-membered aromatic or heteroaromatic ring, wherein R
E
or R
P
is alkyl, hydrogen, hydroxyalkyl or aryl. R
Z
is alkyl, —CH
2
—C≡CR
P
, aryl, arylalkyl, or aroylalkyl. R
1
and R
2
are independently hydrogen, alkyl or hydroxymethyl. R
3
is hydrogen or methyl. R
4
is acetamido, hydrogen, methyl, amino, —C≡CR
E
, —CH
2
—C≡—CR
P
alkylthio, fluoromethyl, difluoromethyl, trifluoromethyl, cyanomethyl, hydroxyalkyl, alkoxycarbonyl-methyl, 1-(alkoxycarbonyl)-1-hydroxyalkyl or aminocarbonylmethyl. (The “1” notations of “1-(alkoxycarbonyl)-1-hydroxyalkyl” indicates that a terminal methyl [but for the recited substitutions] of “alkyl” is substituted with the hydroxyl and esterified carbonyl.)
REFERENCES:
patent: 5853703 (1998-12-01), Cerami et al.
patent: 6121300 (2000-09-01), Wagle et al.
patent: 07033767 (1995-02-01), None
patent: WO 87/05020 (1987-08-01), None
Alteon Inc.
Dechert
Krass Frederick
LandOfFree
Method for treating fibrotic diseases with azolium chroman... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating fibrotic diseases with azolium chroman..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating fibrotic diseases with azolium chroman... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3043978